» Articles » PMID: 29285431

Acute Kidney Injury Aggravated by Treatment Initiation with Apixaban: Another Twist of Anticoagulant-related Nephropathy

Abstract

Anticoagulant-related nephropathy (ARN) was initially described in patients on warfarin (as warfarin-related nephropathy) and recently in those using dabigatran. Herein, we report clinical history and kidney biopsy findings in a patient on apixaban (Eliquis). Initiation of treatment with apixaban resulted in aggravation of preexisting mild acute kidney injury (AKI). A few days after apixaban therapy, the patient became oligoanuric, and kidney biopsy showed severe acute tubular necrosis with numerous occlusive red blood cell casts. Only one out of 68 glomeruli with open capillary loops had small segmental cellular crescent. Therefore, there was major discrepancy between the degree of glomerular injury and the glomerular hematuria. Considering that the onset of this AKI was associated with apixaban treatment initiation, we propose that this patient had ARN associated with factor Xa inhibitor (apixaban), which has not previously been described. Monitoring of kidney function is recommended after initiation of anticoagulant therapy.

Citing Articles

Edoxaban-induced acute interstitial nephritis.

Gen S, Higashi R, Nagae N, Kigure R, Kamikubo Y, Nobe K CEN Case Rep. 2025; .

PMID: 39948237 DOI: 10.1007/s13730-025-00974-7.


An Overlap of Anticoagulant-Related and IgA Nephropathy: A Case Report.

Galloway M, Sim J, Slater A, Bray C, Bishev D, Walker P Glomerular Dis. 2024; 4(1):167-171.

PMID: 39473995 PMC: 11521512. DOI: 10.1159/000541116.


Oral anticoagulant treatment and risk of kidney disease-a nationwide, population-based cohort study.

Vestergaard A, Jensen S, Heide-Jorgensen U, Adelborg K, Birn H, Carrero J Clin Kidney J. 2024; 17(1):sfad252.

PMID: 38186872 PMC: 10768770. DOI: 10.1093/ckj/sfad252.


An Inconspicuous Offender: Apixaban-Induced Anticoagulant-Related Nephropathy.

Shaw D, Kaiser S, Kong A, Joshi S Cureus. 2023; 15(9):e44672.

PMID: 37799236 PMC: 10550341. DOI: 10.7759/cureus.44672.


Challenging clinical scenarios for therapeutic anticoagulation: A practical approach.

Martens K, Dekker S, Crowe M, DeLoughery T, Shatzel J Thromb Res. 2022; 218:72-82.

PMID: 36027629 PMC: 9481720. DOI: 10.1016/j.thromres.2022.08.015.


References
1.
Satoskar A, Suleiman S, Ayoub I, Hemminger J, Parikh S, Brodsky S . Staphylococcus Infection-Associated GN - Spectrum of IgA Staining and Prevalence of ANCA in a Single-Center Cohort. Clin J Am Soc Nephrol. 2016; 12(1):39-49. PMC: 5220658. DOI: 10.2215/CJN.05070516. View

2.
Berger R, Salhanick S, Chase M, Ganetsky M . Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. Ann Emerg Med. 2013; 61(4):475-9. DOI: 10.1016/j.annemergmed.2013.02.008. View

3.
Brodsky S, Nadasdy T, Rovin B, Satoskar A, Nadasdy G, Wu H . Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int. 2011; 80(2):181-9. PMC: 3675881. DOI: 10.1038/ki.2011.44. View

4.
Wheeler D, Giugliano R, Rangaswami J . Anticoagulation-related nephropathy. J Thromb Haemost. 2015; 14(3):461-7. DOI: 10.1111/jth.13229. View

5.
Escoli R, Santos P, Andrade S, Carvalho F . Dabigatran-Related Nephropathy in a Patient with Undiagnosed IgA Nephropathy. Case Rep Nephrol. 2015; 2015:298261. PMC: 4540981. DOI: 10.1155/2015/298261. View